Author:
Yen Hsu-Heng,Su Pei-Yuan,Liu I.-L.ing,Zeng Ya-Huei,Huang Siou-Ping,Hsu Yu-Chun,Hsu Po-Ke,Chen Yang-Yuan
Abstract
Abstract
Background
Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, cirrhosis, and liver cancer. Most of the infected people have no clinical symptoms. The current strategy for HCV elimination includes test and treatment. In this study, we aimed to evaluate the campaign for retrieving patients who were lost to follow-up, for subsequent re-evaluation.
Methods
From January 2020 to October 2020, patients who had prior tests for positive anti-HCV antibody in 2010–2018 in our hospital were enrolled for our patient callback campaign. Patients who had unknown HCV RNA status or no documented successful antiviral therapy history were selected for anti-HCV therapy re-evaluation. To facilitate patient referral in the hospital, we developed an electronic reminding system and called the candidate patients via telephone during the study period.
Results
Through the hospital electronic system, 3783 patients with positive anti-HCV antibody documentation were identified. Among them, 1446 (38.22%) had tested negative for HCV RNA or had anti-HCV therapy, thereby excluded. Of the 2337 eligible patients, 1472 (62.99%) were successfully contacted and called back during the study period for subsequent HCV RNA testing and therapy. We found that 42.19% of the patients had positive HCV RNA and 88% received subsequent anti-HCV therapy.
Conclusions
A significant number of patients with positive HCV serology were lost for HCV confirmatory test or therapy in the hospital. Therefore, this targeted HCV callback approach in the hospital is feasible and effective in achieving microelimination.
Funder
Changhua Christian Hospital
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference27 articles.
1. Chi CT, Chen CY, Su CW, Chen PY, Chu CJ, Lan KH, Lee IC, Hou MC, Huang YH. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. J Microbiol Immunol Infect. 2019;14;S1684–1182(19)30157-4.
2. Liu I-L, Liu T, Zeng Y-H, Huang S-P, Hsu Y-C, Su P-Y, Yen H-H. Interferon-free anti-HCV therapy has a better treatment response rate and adherence than interferon-based therapy for patients with HCV/HIV coinfection: a single-center retrospective study. Changhua J Med. 2020;18(4):122–9.
3. Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, Chen YY, Yang CW, Wu SS, Chou KC. Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS ONE. 2020;15(8):e0237582.
4. Yen HH, Shih KL, Lin TT, Su WW, Soon MS, Liu CS. Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C. World J Gastroenterol. 2012;18(36):5084–9.
5. Hasan F, Alfadhli A, Al-Gharabally A, Alkhaldi M, Colombo M, Lazarus JV. Accelerating the elimination of hepatitis C in Kuwait: an expert opinion. World J Gastroenterol. 2020;26(30):4415–27.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献